MenuMENU
Meetings & Events > Conferences & Courses > Annual Scientific Meeting > 2013 Annual Scientific Meeting > 2013 ASM Syllabus Home Page > Day 3 Agenda and Syllabus

RecycleACMT125wThe Changing Faces of Antidotes

Web-based Syllabus

Instructions:

Lecture slides are available as PDFs in color (1 slide per page) and black & white (3 slides per page). Only material submitted by the lecturer is available.The files contained on these pages are the intellectual property of the American College of Medical Toxicology and, the authors and speakers. No unauthorized download, copy or distribution of these files is permitted.

Click on Color or B&W for the lecture you would like, or right-click and select "Save As..."

Please note that the web-based syllabus will be updated as new or revised material is made available. When re-visiting the syllabus, please refresh your browser to ensure access to recent updates. Breakout sessions may feature handouts that will be made available during individual sessions.

A printed syllabus will not be available for attendees in San Juan. Please print material you require prior to arrival.

 

Day 3

 Sunday, March 17, 2013

 
7:00-8:00am
Committee Meetings

7:00-8:00am   Positions & Guidelines Committee, Miramar Room

7:00-8:00am   2014 ASM Planning Committee, Atlantic Room I

7:00-8:00am   Medication Management Section, Atlantic Room ll

 Committee & Section Meetings Complete Schedule
8:00-9:00am ACMT Business Meeting  
 9:00-10:00am Platform Session 4
Moderators: Suzanne Doyon, MD, FACMT and Tammi H. Schaeffer, DO

Intravenous Lipid Emulsion Does Not Reverse Dabigatran Induced Anticoagulation in a Rat Model
Jared Blum, MD

A Rapid Reconstitution Method for CroFab® Polyvalent Immune Fab (ovine)
David Gerring

Adjunct Ketamine Use in the Management of Severe Alcohol Withdrawal: A Case Series
Nathan Menke, MD

Efficacy of Naltrexone in Preventing Encephalopathy after Poisoning with the Sarin Analogue Diisofluorophosphate in Rats
William J. Meggs, MD, PhD

All Abstracts - JMT PDF
10:00-11:00am Poster Session 2: Authors with Posters  Poster Display List - PDF
11:00-11:15am Break  
11:15-12:00pm Novel Therapies: What Are the Ethical, Legal, and Regulatory Issues?
Christian A. Tomaszewski, MD, FACMT 
B&W 
12:00-12:30pm
National Drug Shortage: Adapt, Overcome, Improvise?
Brenna M. Farmer, MD 
B&W 
 
12:30-1:15pm
 
Homeland Security and Antidote Stockpile
Mark Kirk, MD, FACMT 
 
 
         
 

 

Blum125w Dr. Jared Blum is currently completing his fourth year of residency at the Brown University Emergency Medicine Residency in Providence, Rhode island.  He has been working with the Division of Toxicology over the past 3 years examining the antidotal properties of intravenous lipid emulsion.  His other research interests include author conflicts of interest.
Farmer Dr. Brenna M. Farmer is an attending physician and Assistant Professor of Medicine at Weill-Cornell Medicine College and NY Presbyterian Hospital/Weill-Cornell Campus. She is a member of ACMT and chair of ACMT’s Medication Management Section. She serves as co-chair of NY Presbyterian Hospital’s Adverse Drug Reactions Committee and is a member of the Medication Safety Subcommittee and Drug Shortages Committee.  When she is not working clinically in the Emergency Department or as a consultant on the Medical Toxicology Consultation Service, she teaches residents and students about safe medication practices, overdoses, and other toxicology areas of interest including wilderness medicine topics like bites, stings, and plant poisonings. She will complete a “Comprehensive Patient Safety Leadership Fellowship” through the American Hospital Association and National Patient Safety Foundation in June 2013.
Gerring125

David Gerring is a group leader for the development of speciality pharmaceutical products at BTG.  He gained a graduate degree at Reading University in 1996 and moved on to post graduate education at Oxford University where he used gene profiling and protein expression techniques to identify novel tumour associated antigens in leukaemia and lymphomas.   He then spent several years researching and characterising transmissible spongiform encephalopathy’s before moving into the pharmaceutical sector in 2005.  Here he was involved in the development and licensure of a recombinant humanised anti-TNF monoclonal, used molecular evolution techniques in the advancement of specific T-Cell receptor therapies and was involved in the characterisation of viral platforms for Tuberculosis immunisation before joining BTG in 2011.

Kirk125w Dr. Mark Kirk is an emergency physician and medical toxicologist at the University of Virginia in Charlottesville, Virginia. He is Associate Professor in the School of Medicine’s Department of Emergency Medicine and Department of Pediatrics and he serves as the Medical Director for the UVA Medical Simulation Center.  He has extensive clinical experiences in hazardous materials response, mass gathering medicine and disaster medicine including participation in emergency response planning, mass gathering medicine and NDMS Disaster Medical Assistance Team responses.  He is an educator focusing on critical care toxicology, hazardous materials responses and specifically responses to large-scale incidents.  His teaching is focused on tactical aspects of patient care by translating knowledge into critical decision-making skills and actions.  He recently served as a technical expert and advisor to the Department of Homeland Security. 
Meggs125w
Dr. William J. Meggs is a Medical Toxicologist and Emergency Physician practicing at Vidant Medical Center in Greenville, North Carolina. He is Professor of Emergency Medicine and Chief of the Division of Toxicology at the Brody School of Medicine at East Carolina University. His research interests include chronic effects of organophosphate poisoning and first aid and other treatments for poisonous snake and spider bites. He was a toxicology fellow at the New York City Poison Center and the recipient of the 2010 American College of Medical Toxicology award for outstanding contributions to toxicology research. 
Menke125w

Dr.Nathan Menke is a second year medical toxicology fellow at the University of Pittsburgh Medical Center. Dr. Menke received his medical degree at the Ohio State University in 2002; he completed his Emergency Medicine Residency at the Medical College of Virginia in 2005.  Dr. Menke completed his Ph.D. in Biochemistry and Molecular Biology from Virginia Commonwealth University in 2010.  Dr. Menke is board-certified in Emergency Medicine.

Tomaszewski125w

Dr. Christian A. Tomaszewski is faculty member at the emergency medicine residency at the University of California San Diego.  After training in EM at East Carolina University, he completed at clinical toxicology fellowship at Rocky Mountain Poison Center in Denver.  Simultaneously he trained and became boarded in underwater and hyperbaric medicine as well.  After serving as toxicology fellowship director and medical director of hyperbaric medicine at Carolinas Medical Center, he completed two emergency medicine enhancement projects in United Arab Emirates and Qatar.   After four years abroad, he joined the faculty at the UCSD, where he serves as associate director of emergency clinical services as well associate medical director for the local poison center.  His research interests continue to include carbon monoxide, cardiovascular toxins, and medication safety.